Kallisio
Kallisio develops patient-specific 3D-printed oral immobilization devices for head and neck cancer radiation therapy, anchored by its FDA-cleared and CE-marked Stentra™ system.
- CEO / Founder
- Rajan Patel
- Team Size
- 1-10
- Stage
- Growth Stage
- Key Investors
- iO Life Ventures
Technology & Products
Key Products
Stentra™ — FDA 510(k)-cleared and CE-marked patient-specific 3D-printed intraoral immobilization and positioning device for head and neck cancer radiation therapy; cloud-based clinical portal ordering system; intraoral scanning workflow integration
Technological Advantage
Digital workflow from intraoral scan to automated design to 3D printing to delivery in 72 hours; biocompatible medical-grade resin; cloud-based clinical portal; CPT-reimbursable code (77334); scaling via RICOH's network of FDA-registered 3D printing facilities
Differentiation
Value Proposition
Sub-millimeter precision 3D-printed custom oral immobilization devices delivered in 72 hours that reduce radiation side effects in head and neck cancer patients, are CPT-reimbursable, and integrate into existing clinical workflows.
How They Differentiate
Fully patient-customized (not pre-formed or semi-custom); sub-millimeter precision fit via 3D printing from intraoral scan; 72-hour turnaround from scan to delivery; CPT-reimbursable (CPT 77334); technology exclusively licensed from MD Anderson Cancer Center; clinical studies showing reduction in severe oral mucositis
Market & Competition
Target Customers
Radiation oncology departments at cancer centers and hospitals; head and neck cancer patients undergoing radiotherapy
Industry Verticals
Medical devices; Radiation oncology; Head and neck cancer treatment; Precision medicine
Competitors
3D Systems (Healthcare); IZI Medical Products; Qfix/Civco Radiotherapy
Growth & Milestones
Major Milestones
Founded 2022; FDA 510(k) clearance for Stentra (January 2024); Exclusive technology license from MD Anderson Cancer Center; Strategic partnership with RICOH 3D for Healthcare (September 2024); Clinical implementation at leading cancer centers (December 2025); CE Mark certification under EU MDR (March 2026); Named Best New Radiology Technology Solution in MedTech Breakthrough Awards (May 2026); Texas Cancer Institute adopts Stentra as standard of care (May 2026)
Notable Customers
MD Anderson Cancer Center; Stanford Health Care; Penn Medicine; Fox Chase Cancer Center; Texas Cancer Institute